Medical and psychosocial considerations in rehabilitation care of childhood neuromuscular diseases

Handbook of Clinical Neurology

Volumn 113, Issue , 2013, Pages 1491-1495

  Vanasse, Michel ^a   Paré, Hélène ^a   Zeller, Reinhard ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876840438     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59565-2.00019-8     Document Type: Chapter

References (20)

1. Abi-Daoud M., Dooley J.M., Gordon K.E. Depression in parents of children with Duchenne muscular dystrophy. Pediatr Neurol 2004, 31:16-19.
2. Alman B.A. Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. J Pediatr Orthop 2005, 25:554-556.
3. Association Française contre les Myopathies (AFM) Fiche technique: avancées médico-scientifiques neuromusculaires 2008, AFM, Paris, p. 31.
4. Bax M.C.O. Disclosure. Dev Med Child Neurol 2002, 44:579.
5. Boström K., Ahlström G. Living with a chronic deteriorating disease: the trajectory with muscular dystrophy over ten years. Disabil Rehabil 2004, 23:1388-1398.
6. Boström K., Nätterlund B.S., Ahlström G. Sickness impact in people with muscular dystrophy: a longitudinal study over 10 years. Clin Rehabil 2005, 19:686-694.
7. Deschaintre Y., Fortier R., Morais L., et al. Approche multidisciplinaire de l'annonce d'un diagnostic de maladie évolutive. Les Soins Palliatifs Pédiatriques 2004, 449-459. Les éditions de l'Hôpital Sainte-Justine. N. Humbert (Ed.).
8. Desguerre I., Christov C., Mayer M., et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 2009, 4:e4347.
9. Di Prospero N.A., Baker A., Jeffries N., et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007, 6:878-886.
10. Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. Proc R Soc Med 1973, 66:219-220.
11. Duval-Beaupere G., Poiffaut A., Bouvier C.L., et al. Molded plexidur corrective corsets in the treatment of paralytic scolioses. Evaluation after 7 years usage. Acta Orthop Belg 1975, 41:652-659.
12. Émond M., Vanasse M., Pandolfo M. Pilot trial of idebenone in children with Friedreich ataxia 2001, American Academy of Neurology Annual. Meeting, Philadelphia.
13. Graungaard A.H., Skov L. Why do we need a diagnosis? A qualitative study of parents' experiences, coping and needs, when the newborn child is severely disabled. Child Care Health Dev 2006, 33:296-307.
14. Houde S., Filiatrault M., Fournier A., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008, 38:200-206.
15. McLaughlin J. Exploring diagnostic processes: social science perspectives. Arch Dis Child 2005, 90:284-287.
16. Manzur A.Y., Kuntzer T., Pike M., et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy 2008, Cochrane Database Syst Rev Art. No.: CD003725.
17. Muntoni F., Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007, 20:590-594.
18. Nätterlund B., Ahlström G. Activities of daily living and quality of life in persons with muscular dystrophy. J Rehabil Med 2001, 33:206-211.
19. Russman B.S. Rehabilitation of the child with a neuromuscular disorder. Neuromuscular Disorders of Infancy, Childhood and Adolescence 2004, 1275-1278. Butterworth Heinemann, Amsterdam. H. Royden-Jones, D.C. De Vivo, B.T. Darras (Eds.).
20. Shone S.M., Ryan S., Rigby P.J., et al. Toward a comprehensive evaluation of the impact of electronic aids to daily living: evaluation of consumer satisfaction. Disabil Rehabil 2002, 24:115-125.